None listed
Conditions
Interventions
Dietary Supplement : Participants will take one tablet per day for 12 weeks with an adequate amount of water. The tablet will either contain 500 mg of marigold and basil composite extract powder or co
Sponsors
Global Medical Research Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) subjects who voluntarily agree to participate and signs informed consent form 2) aged 40 to 74 years 3) experiencing knee joint discomfort 4) with knee joint pain above a certain level
Exclusion criteria
Exclusion criteria: 1)Individuals administered non-steroidal anti-inflammatory drugs or steroid medications within one week prior to the first visit. 2) Individuals diagnosed with inflammatory joint disorders. 3) Individuals with a BMI less than 18.5 kg/m² or greater than 30 kg/m². 5) Individuals with neurological or lower limb joint abnormalities that impair walking, apart from age-related knee discomfort. 6) Individuals with a history of knee joint surgery. 7) Individuals reporting moderate to severe back pain and radiating leg pain. 7) Individuals with meniscal tears or severe neurological and vascular disorders of the lower limbs. 8) Individuals with liver dysfunction. 9) Individuals with kidney dysfunction. 10) Individuals currently being treated for gastritis or gastric ulcers. 11) Individuals currently undergoing treatment for severe cardiovascular, immune, respiratory, hepatobiliary, renal, urological, neurological, musculoskeletal, infectious diseases, or malignancies. 12) Individuals diagnosed with dementia or intellectual disabilities, or those who are illiterate. 13) Alcohol-dependent individuals. 14) Excessive smokers. 15) Individuals who have taken arthritis-related medications within 4 weeks prior to the first visit or systemic/intra-articular hyaluronate or glucocorticoids within 12 weeks prior to the first visit. 16) Individuals who have regularly consumed health supplements that could affect joint health within 4 weeks prior to the first visit. 17) Individuals who have consumed components or products that might influence joint inflammation levels within 4 weeks prior to the first visit. 18) Individuals who have participated in other clinical trials within 4 weeks prior to the first visit or plan to participate in other clinical trials during this study. 19) Pregnant or breastfeeding individuals, or those planning to conceive during this study. 20) Individuals with hypersensitivity to components in the test/control food or those with a history of severe allergic reactions to food. 21) Individuals deemed unsuitable for participation in this study by the researcher.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Western Ontario and McMaster University Osteoarthritis Index;Visual Analogue Scale | — |
Secondary
| Measure | Time frame |
|---|---|
| biomarker(high sensitivity C-reactive protein, erythrocyte sedimentation rate, cartilage oligomeric matrix protein, etc.) ;Laboratory test(blood, urine), etc. | — |
Countries
Korea, Republic of
Contacts
Public ContactHanKook Yoon
National Health Insurance Service Ilsan Hospital
Outcome results
None listed